Histologically, gastric carcinoma demonstrates marked heterogeneity at both the architectural and cytologic levels, often with the coexistence of several histologic elements. Signet ring cell carcinoma (SRC) is a form of adenocarcinoma (AC) whose histologic diagnosis is based on microscopic characteristics defined by the World Health Organization (WHO).^[@R1]^ The predominant component is scattered malignant cells containing intracytoplasmic mucin, which occupies more than 50% of tumors. SRC and non-SRC are thought to be distinct biologic entities originating from different sources of carcinogenesis. Based on histologic findings that SRC is poorly cohesive and has a propensity to invade via submucosal and subserosal routes, worse prognosis of SRC or diffuse-type gastric cancer has been suggested by early Western studies.^[@R2]--[@R4]^ However, several noncomparative Asian studies have begun to question this idea,^[@R5],[@R6]^ and only recently, a large-volume study from the United States demonstrated that after adjusting for age, SRC does not necessarily portend a worse prognosis.^[@R7]^ Moreover, several comparative studies have suggested that the prognostic impact of SRC may be dependent on disease stage, although this remains controversial.^[@R8]^ These discrepancies can be explained---at least partly---by the methodology and design variations of each study, the interpersonal discrepancies regarding pathologic definitions, the heterogeneity of non-SRC groups according to tumor grade, and the insufficiency of stage-stratified analyses for comparison. Therefore, for better understanding of the prognostic impact of SRC, a larger volume of patients exhibiting consistency in the surgical technique applied and pathological diagnosis are necessary, and a comparative analysis with non-SRC patients according to tumor grade. Asian gastric cancers are characterized by (i) earlier tumor stage at diagnosis based on nationwide mass screening; (ii) a more consistent surgical approach including extended lymph node dissection (D2); and (iii) consensual adjuvant chemotherapy. Herein, we compared SRC with well-to-moderately differentiated (WMD) and poorly differentiated (PD) tubular AC in patients who underwent radical gastrectomy.

PATIENTS AND METHODS
====================

Patient Selection
-----------------

This study included patients who underwent curative (R0) resection of gastric cancer at Severance Hospital, Seoul, Korea, from January 2001 to December 2010. The main selection criteria were as follows: (i) pathologically confirmed tubular AC or SRC and (ii) available documented information regarding the primary tumor site, postoperative pathological stage, surgery, and survival. The main exclusion criteria were as follows: (i) patients who received neoadjuvant chemo(radio)therapy, (ii) metastatic disease, and (iii) concurrent double primary cancer. Thus, 712 of 8379 selected patients were excluded (Fig. [1](#F1){ref-type="fig"}). A predesigned data collection format was used to extract the data from a prospectively maintained database. The pathologic stage was classified according to the American Joint Committee on Cancer (AJCC) staging manual (7th edition). This study was approved by the Institutional Review Board of Severance Hospital.

![CONSORT diagram. AJCC, American Joint Committee on Cancer, 7th edition.](ansu-265-946-g001){#F1}

All specimens, including the resected stomach and regional lymph nodes, were histologically examined by independent pathologists. Based on the WHO definition, SRC was defined as the predominance (\>50%) of isolated carcinoma cells containing intracytoplasmic mucin that pushes the nucleus to the cell periphery. Tubular AC was also classified as well (well-formed glands, often resembling metaplastic intestinal epithelium), moderately, or poorly differentiated (highly irregular glands that are recognized with difficulty) according to the WHO classification.^[@R1]^ We divided the patients into three groups: SRC, WMD, and PD for further evalution.

Statistical Analysis
--------------------

The cutoff date was August 31, 2014 with a maximum follow-up period of 10 years. The basic demographic and clinical characteristics among groups were compared using independent *t* tests and χ^2^ tests. For pair-wise comparison of each level of categorical variables, statistical significance was adjusted for inflated Type I error from multiple comparisons using the Bonferroni method.

Relapse-free survival (RFS) was measured from the time of surgery to initial tumor relapse (local recurrence or distant), and overall survival (OS) was calculated as the time from surgery to death of any cause or the last follow-up date. Survival curves were generated using the Kaplan-Meier (KM) method and then compared with the log-rank test. Cox proportional hazard model was used for multivariable analysis of prognostic factors, including age at diagnosis, sex, stage, and histologic type. Statistical significance was set as *P* \< 0.05 for all analyses. All statistical analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL).

RESULTS
=======

Patient Demographics
--------------------

A total of 7667 patients who underwent curative resection of tubular AC or SRC were analyzed. As depicted in Table [1](#T1){ref-type="table"}, 1646 patients (21.5%) had SRC, and 6021 patients (78.5%) were recorded as having tubular AC. Of these tubular AC patients, 1136 (14.8%) were well differentiated, 2267 (29.6%) were moderately differentiated, and the remaining 2618 (34.1%) were PD.

The age at initial diagnosis was younger in SRC patients than in WMD or PD patients (SRC: 52 yrs; WMD: 61 yrs; PD: 56 yrs; SRC vs WMD and PD: *t* test *P* \< 0.001). The peak age range of SRC patients was 41 to 50 years, whereas it was 61 to 70 years for both the WMD and PD groups, reaffirming that the SRC group had a different age distribution. In addition, SRC had a higher percentage of females (SRC: 50.6%; WMD: 22.8%; PD: 38.2%; SRC vs WMD and PD: χ^2^*P* \< 0.001).

Tumor Presentation
------------------

At initial diagnosis, 61.9% of SRC patients were at stage IA, whereas 58.2% of WMD patients and only 29.7% of PD patients were diagnosed as stage IA (SRC vs WMD: χ^2^*P=* 0.024; SRC vs PD: χ^2^*P* \< 0.001) (Table [2](#T2){ref-type="table"}). Meanwhile, SRC was less likely to be presented at intermediate stages extending from stages IB to IIIA. In terms of tumor (T) and nodal (N) stages, a higher proportion of patients with SRC presented with T1a in which the tumor was contained only in the mucosal layer (SRC: 46.5%; WMD: 31.8%; PD: 14.7%; SRC vs WMD and PD: χ^2^*P* \< 0.001) and N0 (SRC: 74.2%; WMD: 71.6%; PD: 47.7%; SRC vs WMD: χ^2^*P=* 0.105; SRC vs PD: χ^2^*P* \< 0.001). Similar to the stage distribution, patients with SRC were less likely to present at intermediate tumor (T2 and T3) and nodal stages (N1 and N2). The anatomic locations of tumors and Lauren\'s classification of each subtype are shown in Table [3](#T3){ref-type="table"}.

Similar to other subtypes, SRC was found mostly in the lower third of the stomach. In terms of Lauren\'s classification, most SRC (96.4%) were classified as diffuse-type, and most cases of WMD (94.8%) were classified as intestinal-type. In cases of PD, 61.1% were classified as diffuse-type, whereas 27.8% were intestinal-type.

Survival
--------

The median length of follow up was 63.9 months. KM curves according to pathologic classification are shown in Figure [2](#F2){ref-type="fig"}. SRC had significantly better OS than non-SRC (10 year OS: 80% vs 70%; *P* \< 0.001; Fig. [2](#F2){ref-type="fig"}A). Intriguingly, when all patients were divided into early gastric cancer (EGC) and advanced gastric cancer (AGC) groups, SRC displayed significantly better survival than non-SRC in EGC (10 yr OS: 95% vs 85%; *P* \< 0.001; Fig. [2](#F2){ref-type="fig"}B); however, the survival was overturned in AGC (10 yr OS: 53% vs 54%; *P* = 0.049; Fig. [2](#F2){ref-type="fig"}C).

![(A--C) Kaplan-Meier (KM) survival curves of tubular adenocarcinoma (AC) and signet ring cell carcinoma (SRC) are shown for (A) overall survival (OS) of all stages, (B) OS of early gastric cancer (EGC), and (C) OS of advanced gastric cancer (AGC). (D) KM curves comparing the OS of patients with well differentiated (WD), moderately differentiated (MD), and poorly differentiated (PD) tubular AC and SRC at all stages. (E--I) KM curves comparing the OS of patients with well-to-moderately differentiated (WMD) and poorly differentiated (PD) tubular AC and SRC at: (E) EGC, (F) AGC, (G) American Joint Committee on Cancer, 7th^h^ edition (AJCC) stage I, (H) AJCC stage II, and (I) AJCC stage III.](ansu-265-946-g002){#F2}

We then compared the OS of SRC with that of non-SRC after dividing the latter into WMD and PD groups (Figs. [2](#F2){ref-type="fig"}E--I). By peforming a pair-wise comparison, we found that SRC showed a significantly better OS than both WMD and PD in EGC (10 yr OS: SRC: 95%; WMD: 84%; PD 89%; SRC vs WMD and PD: *P* \< 0.001; Fig. [2](#F2){ref-type="fig"}E). Interestingly, the OS of PD was significantly longer than WMD (KM *P* \< 0.001). On the other hand, SRC and PD demonstrated significantly worse OS than WMD in AGC (10 yr OS: SRC: 53%; WMD: 58%; PD: 52%; WMD vs SRC and PD: *P* \< 0.001; Fig. [2](#F2){ref-type="fig"}F). However, the OS of SRC and PD were not significantly different on pair-wise comparison analysis.

Regarding to individual stages, SRC showed the best survival outcome, followed by PD and WMD in stage I (10 yr OS: SRC: 96%; PD: 89%; WMD 83%; SRC vs WMD and PD: *P* \< 0.001; Fig. [2](#F2){ref-type="fig"}G). Meanwhile, in stage II, no statistically significant differences were observed among the three groups. In stage III, the worst survival was observed for SRC, followed by PD and WMD (10 yr OS: SRC: 32%; PD: 37%; WMD 40%; SRC vs WMD: *P* \< 0.001; SRC vs PD: *P* = 0.086; Fig. [2](#F2){ref-type="fig"}G). These survival trends were also applied to the RFS of respective groups, as shown in Supplementary Figure 1.

Predictors of Recurrence and Mortality
--------------------------------------

The unadjusted bivariate analysis results of the RFS and OS of all patients are shown in Supplementary Table 1. In all patients, SRC (vs non-SRC) was the factor associated with reduced recurrence and mortality. However, when compared with WMD, SRC was not associated with recurrence and mortality.

Thereafter, we performed an unadjusted analysis for RFS and OS divided by EGC and AGC (Table [4](#T4){ref-type="table"}). In EGC, SRC was associated with reduced recurrence and mortality, comparing both with non-SRC and WMD. Meanwhile, in AGC, SRC (vs WMD) was associated with increased recurrence and mortality, and SRC (vs non-SRC) displayed a borderline significance in increased recurrence and mortality in AGC (RFS: Cox hazard ratio, (HR) 1.15; 95% confidence interval (CI) 0.99 to 1.34; *P=* 0.066; OS: Cox HR 1.15; 95% CI 1.00 to 1.33; *P=* 0.050).

Multivariable analysis results for EGC and AGC using Cox\'s proportional hazard model after adjustments for age, sex, and stage are listed in Table [5](#T5){ref-type="table"} and Supplementary Table 2. SRC (vs WMD) was an independent favorable predictor of recurrence and mortality in EGC (RFS: Cox HR 0.37; 95% CI 0.19 to 0.71; *P* = 0.003; OS: Cox HR 0.66; 95% CI 0.44 to 0.98; *P=* 0.041). On the other hand, in AGC, SRC (vs WMD) was an unfavorable predictor of RFS and OS (RFS: Cox HR 1.22; 95% CI 1.02 to 1.46; *P* = 0.033; OS: Cox HR 1.45; 95% CI 1.22 to 1.71; *P* \< 0.001). In the case of SRC (vs non-SRC), whereas it was an independent favorable predictor of recurrence and mortality in EGC (RFS: Cox HR 0.40; 95% CI 0.21 to 0.76; *P* = 0.005; OS: Cox HR 0.66; 95% CI 0.45 to 0.99; *P* = 0.043), it had no significant value in predicting recurrence in AGC (RFS: Cox HR 1.11; 95% CI 0.96 to 1.30; *P* = 0.170).

DISCUSSION
==========

Traditionally, gastric cancer has been classified by two morphological differences: intestinal type and diffuse type. In males, intestinal type is more common, and the incidence rises faster with age, whereas diffuse type affects younger people---frequently females. The recent decline in the overall incidence of gastric cancer in Asia stems from the decrease in intestinal type and has been correlated with the corresponding decrease in *Helicobacter* infestation.^[@R9]^ However, diffuse type, which is uniformly distributed worldwide and continues to increase, is worrisome given that it is thought by Western researchers to have a worse prognosis. Asian researchers have asserted that SRC is not necessarily prognostically worse than non-SRC. However, many of the studies have included only small-sized heterogenous patients including unresected or noncuratively resected cases, early-stage disease, and even metastatic disease. In addition, most studies compared SRC with heterogeneous non-SRC tumors after merging them into a single group. Thus, to the best of our knowledge, this study currently has the largest dataset for SRC analysis in Asia in which we enrolled only patients who were guaranteed to have had D2 dissection and R0 disease, believing that a more clarified natural course of SRC can be obtained from a more homogenous dataset. Furthermore, tubular AC, which comprises the largest portion of gastric cancer, was redivided according to the differentiation, which enables the correction of internal heterogeneity within the group.

We reaffirmed that SRC in an Asian population has distinct features from those of tubular AC. First, the stage distribution at diagnosis was skewed to early-stage, and 60% of SRC cases were EGC. This finding did not align with a previous study that reported a more frequent presentation in late-stage.^[@R7]^ This finding may be largely because of the nationally sponsored screening program. The second feature was the transition of prognosis as disease progressed. Although SRC in EGC had better survival than non-SRC, this was reversed in AGC, with SRC showing a worse prognosis than non-SRC and particularly WMD. These results might suggest that driver mutations controlling the metastatic potential of SRC can occur late in the course of disease. The third feature was early-age onset and a higher female ratio, which was in accordance with previous studies. We observed an onset that was about 7 years earlier in SRC patients than in tubular AC patients, and over half of the patients were female, despite the fact that gastric cancer is widely known to be a male-dominant cancer. All of these findings strengthen the idea that SRC is a form of disease distinct from tubular AC.^[@R10]--[@R12]^

The characteristics and prognosis of SRC mentioned above are similar to those suggested in hereditary diffuse gastric cancer (HDGC). HDGC is a disease inherited by autosomal dominant patterns and is characterized by the early-age onset of SRC. SRC in HDGC has the unique characteristic of being indolent in the mucosal layer for a prolonged period at early stages, although eventually displaying aggressive phenotypes, and such traits of HDGC are similar to those shown by SRC in this study. The E-cadherin (*CDH1*) gene was reported to be relevant to HDGC; however, the germ-line mutation of the *CDH1* gene comprised only 1% to 3% of gastric cancer.^[@R13],[@R14]^ However, recently published studies have revealed that somatic mutations of the *CDH1* gene are also relevant to diffuse-type gastric cancer.^[@R15],[@R16]^ Therefore, further study is warranted to provide clues regarding the genetic alterations of SRC and its drastic prognosis change.

We believe that stage-adjusted analysis is important in clarifying the prognosis of SRC, which may explain why Western countries that have low EGC prevalence have reported that SRC has a poor prognosis. However, Asian countries that have a widely accepted early detection program, a standardized surgical procedure, and prevailing adjuvant therapy have recently criticized this idea. They have tried to compare the prognosis between SRC and non-SRC; however, the small sample size has been a limitation.^[@R6],[@R17],[@R18]^ A recent American study utilizing Surveillance, Epidemiology, and End Results data adopted stage adjustment to overcome these limitations and demonstrated that SRC is not a negative prognostic indicator.^[@R7]^ However, a large proportion of the patients did not undergo surgical resection, meaning that concerns exist with respect to the reliability of stage and the application of the exact definition of SRC. In addition, it compared SRC with non-SRC after merging non-SRC tumors into a single group for outcome comparison, which is an oversimplification of this heterogeneous disease. This study also demonstrated that SRC confers worse prognosis than WMD in AGC. However, this difference in prognosis was not observed when SRC was compared with non-SRC tumors in terms of recurrence, as PD that has a similar prognosis to that of SRC in AGC was included in the non-SRC group. In this aspect, our study was in line with the report by Bamboat et al,^8^ which, despite its small sample size, suggested that the prognosis of SRC could be stage-dependent.

Another point of this study was the fact that long-term survival data was used, including recurrence status (collected from a close follow-up program); however, this data also limited our study because of the retrospective nature of its collection. In addition, this study only included patients with surgically resected cancer and did not involve patients with metastatic disease, limiting our knowledge of the full spectrum of SRC. However, as patients with stage IV disease are treated with palliation-aimed chemotherapy, they may show different prognoses; thus, another study that analyzes this particular cohort of patients is needed. Another limitation of the current study was the differences in gastric cancer biology between Eastern and Western countries. Because this study was performed only with Asians, the presented data cannot represent the characteristics of western gastric cancer, where cancers of esophagogastric junction and upper stomach were predominant. Therefore, further stage-adjusted studies for western SRC gastric cancer are required to confirm the findings of the current study.

CONCLUSIONS
===========

This study suggests that early-stage SRC could be indolent, demonstrating that more than half of SRC cases are presented as EGC. In addition, SRC in EGC confers a more favorable prognosis after curative resection than WMD. On the other hand, SRC in AGC bestows a worse prognosis than WMD. Therefore, the context-dependent nature of SRC must be considered when predicting its prognostic impact.
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###### 

Demographic Characteristics of Study Subjects

                       Signet Ring Cell Carcinoma (A) (N = 1646)   Well and Moderately Differentiated AC (B) (N = 3403)          Poorly Differentiated AC (C) (N = 2618)                           
  -------------------- ------------------------------------------- ------------------------------------------------------ ------ ----------------------------------------- --------- ------ ------ ---------
  Female sex           833                                         50.6                                                   775    22.8                                      \<0.001   1000   38.2   \<0.001
  Age, yrs                                                                                                                                                                                         
   Mean                51.8                                                                                               60.7                                             \<0.001   55.6          \<0.001
   SD                  12.0                                                                                               10.2                                                       12.3          
  Distribution (yrs)                                                                                                                                                                               
   15--30              49                                          3.0                                                    18     0.5                                       \<0.001   43     1.6    0.007
   31--40              276                                         16.8                                                   106    3.1                                       \<0.001   287    11.0   \<0.001
   41--50              459                                         27.9                                                   423    12.4                                      \<0.001   581    22.2   \<0.001
   51--60              431                                         26.2                                                   975    28.7                                      0.134     684    26.1   0.999
   61--70              341                                         20.7                                                   1366   40.1                                      \<0.001   733    28.0   \<0.001
   71--80              83                                          5.0                                                    473    13.9                                      \<0.001   260    9.9    \<0.001
   81--95              7                                           0.4                                                    42     1.2                                       0.012     30     1.1    0.027

AC indicates adenocarcinoma; SD, standard deviation.

###### 

Tumor Characteristics at Presentation

                Signet Ring Cell Carcinoma (A)   Well and Moderately Differentiated AC (B)           Poorly Differentiated AC (C)                            
  ------------- -------------------------------- ------------------------------------------- ------- ------------------------------ ---------- ------ ------ ---------
  AJCC stage                                                                                                                                                 
   1A           1019                             61.9                                        1,981   58.2                           0.024      778    29.7   \<0.001
   1B           124                              7.5                                         395     11.6                           \< 0.001   274    10.5   0.003
   2A           90                               5.5                                         263     7.7                            0.006      224    8.6    \<0.001
   2B           101                              6.1                                         215     6.3                            0.999      335    12.8   \<0.001
   3A           74                               4.5                                         194     5.7                            0.147      243    9.3    \<0.001
   3B           85                               5.2                                         177     5.2                            0.999      305    11.7   \<0.001
   3C           153                              9.3                                         178     5.2                            \<0.001    459    17.5   \<0.001
  Tumor stage                                                                                                                                                
   T1a          766                              46.5                                        1,081   31.8                           \<0.001    384    14.7   \<0.001
   T1b          325                              19.7                                        1,100   32.3                           \<0.001    529    20.2   0.999
   T2           119                              7.2                                         408     12.0                           \<0.001    363    13.9   \<0.001
   T3           107                              6.5                                         376     11.0                           \<0.001    380    14.5   \<0.001
   T4a          318                              19.3                                        431     12.7                           \<0.001    935    35.7   \<0.001
   T4b          11                               0.7                                         7       0.2                            0.019      27     1.0    0.439
  Node stage                                                                                                                                                 
   N0           1222                             74.2                                        2438    71.6                           0.105      1248   47.7   \<0.001
   N1           118                              7.2                                         406     11.9                           \<0.001    384    14.7   \<0.001
   N2           112                              6.8                                         266     7.8                            0.400      389    14.9   \<0.001
   N3a          105                              6.4                                         207     6.1                            0.999      356    13.6   \<0.001
   N3b          89                               5.4                                         86      2.5                            \<0.001    241    9.2    \<0.001

AJCC indicates American Joint Committee on cancer, 7th edition

###### 

Anatomic Location of Tumor in the Stomach and Lauren\'s Classification

                                                                Signet Ring Cell Carcinoma (A)   Well and Moderately Differentiated AC (B)          Poorly Differentiated AC (C)                           
  ------------------------------------------------------------- -------------------------------- ------------------------------------------- ------ ------------------------------ --------- ------ ------ ---------
  Location                                                                                                                                                                                                 
   Upper                                                        173                              10.5                                        374    11.0                           0.999     417    15.9   \<0.001
   Middle                                                       648                              39.4                                        850    25.0                           \<0.001   916    35.0   0.008
   Lower                                                        819                              49.8                                        2175   63.9                           \<0.001   1276   48.7   0.999
   Whole                                                        6                                0.4                                         4      0.1                            0.064     9      0.3    0.999
  Lauren\'s classification[^\*^](#TF3-1){ref-type="table-fn"}                                                                                                                                              
   Intestinal                                                   14                               1.2                                         2273   94.8                           \<0.001   514    27.8   \<0.001
   Diffuse                                                      1160                             96.4                                        41     1.7                            \<0.001   1131   61.1   \<0.001
   Mixed                                                        29                               2.4                                         84     3.5                            0.152     207    11.2   \<0.001

^\*^5453 of 7667 patients with available data were categorized according to Lauren\'s classification.

###### 

Unadjusted Factors Associated with Overall Survival in EGC and AGC

                                                RFS     OS                                              
  --------------------------------------------- ------- --------------- --------- ------ -------------- ---------
                                                EGC                                                     
  WHO histology and grade                                                                               
   PD (vs WMD)                                  0.82    0.53 to 1.26    0.357     0.73   0.54 to 0.98   0.036
   SRC (vs WMD)                                 0.26    0.14 to 0.49    \<0.001   0.30   0.20 to 0.45   \<0.001
  SRC (vs non-SRC)                              0.28    0.15 to 0.52    \<0.001   0.33   0.22 to 0.48   \<0.001
  Age at diagnosis                              1.03    1.01 to 1.04    0.002     1.09   1.07 to 1.10   \<0.001
  Female sex                                    0.55    0.36 to 0.84    0.005     0.45   0.34 to 0.61   \<0.001
  AJCC stage II (vs stage I)                    7.22    4.59 to 11.37   \<0.001   3.08   2.03 to 4.69   \<0.001
  Submucosal invasion                           2.02    1.40 to 2.92    \<0.001   1.65   1.30 to 2.09   \<0.001
  Lymph node metastasis                         6.15    4.27 to 8.88    \<0.001   2.43   1.80 to 3.28   \<0.001
  Location[^\*^](#TF4-1){ref-type="table-fn"}                                                           
   Middle (vs upper)                            1.60    0.67 to 3.80    0.289     0.99   0.64 to 1.53   0.952
   Lower (vs upper)                             2.10    0.92 to 4.81    0.080     0.93   0.61 to 1.42   0.735
                                                AGC                                                     
  WHO histology and grade                                                                               
   PD (vs WMD)                                  1.40    1.23 to 1.60    \<0.001   1.31   1.16 to 1.49   \<0.001
   SRC (vs WMD)                                 1.42    1.19 to 1.69    \<0.001   1.36   1.15 to 1.60   \<0.001
  SRC (vs non-SRC)                              1.15    0.99 to 1.34    0.066     1.15   1.00 to 1.33   0.050
  Age at diagnosis                              1.00    1.00 to 1.01    0.650     1.02   1.02 to 1.03   \<0.001
  Female sex                                    1.13    1.00 to 1.27    0.051     1.05   0.93 to 1.17   0.452
  AJCC stage                                                                                            
   Stage II (vs stage I)                        3.72    2.50 to 5.53    \<0.001   2.14   1.61 to 2.83   \<0.001
   Stage III (vs stage I)                       14.20   9.75 to 20.68   \<0.001   7.02   5.42 to 9.09   \<0.001
  Tumor stage                                                                                           
   T3 (vs T2)                                   2.28    1.80 to 2.89    \<0.001   1.90   1.55 to 2.33   \<0.001
   T4 (vs T2)                                   5.75    4.68 to 7.06    \<0.001   4.24   3.57 to 5.05   \<0.001
  Node stage                                                                                            
   N1 (vs N0)                                   2.29    1.82 to 2.90    \<0.001   1.69   1.38 to 2.07   \<0.001
   N2 (vs N0)                                   3.91    3.16 to 4.84    \<0.001   2.64   2.19 to 3.18   \<0.001
   N3 (vs N0)                                   8.82    7.29 to 10.67   \<0.001   6.31   5.39 to 7.40   \<0.001
  Location                                                                                              
   Middle (vs upper)                            0.96    0.81 to 1.15    0.684     0.97   0.82 to 1.14   0.683
   Lower (vs upper)                             1.05    0.89 to 1.24    0.566     1.05   0.90 to 1.23   0.532
   Whole (vs upper)                             2.98    1.53 to 5.83    0.001     5.35   3.11 to 9.20   \<0.001

AGC indicates advanced gastric cancer; CI, confidence interval, EGC, early gastric cancer; HR, hazard ratio; PD, poorly differentiated; SRC, signet ring cell carcinoma; WMD, well-to-moderately differentiated.

^\*^Only two EGC patients had 'whole stomach' cancers and were therefore excluded from analysis.

###### 

Multiple Variable Model Predicting Risk of Recurrence and Mortality

                            RFS     OS                                              
  ------------------------- ------- --------------- --------- ------ -------------- ---------
                            EGC                                                     
  Age                       1.02    1.00 to 1.03    0.072     1.08   1.07 to 1.09   \<0.001
  Female                    0.65    0.42 to 1.00    0.050     0.53   0.40 to 0.72   \<0.001
  Submucosal invasion       1.04    0.68 to 1.57    0.870     1.15   0.89 to 1.48   0.286
  LN metastasis             6.00    3.95 to 9.02    \<0.001   2.23   1.62 to 3.07   \<0.001
  Histology and grade                                                               
   PD (vs WMD)              0.77    0.50 to 1.20    0.255     0.96   0.71 to 1.29   0.772
   SRC (vs WMD)             0.37    0.19 to 0.71    0.003     0.66   0.44 to 0.98   0.041
                            AGC                                                     
  Age                       1.00    1.00 to 1.01    0.138     1.02   1.02 to 1.03   \<0.001
  Female                    1.09    0.96 to 1.24    0.168     1.04   0.93 to 1.17   0.490
  AJCC stage                                                                        
   Stage II (vs stage I)    3.67    2.47 to 5.46    \<0.001   2.12   1.60 to 2.81   \<0.001
   Stage III (vs stage I)   13.87   9.52 to 20.21   \<0.001   6.89   5.32 to 8.93   \<0.001
  Histology and grade                                                               
   PD (vs WMD)              1.14    0.99 to 1.31    0.063     1.23   1.09 to 1.40   0.001
   SRC (vs WMD)             1.22    1.02 to 1.46    0.033     1.45   1.22 to 1.71   \<0.001

AGC indicates advanced gastric cancer; CI, confidence interval, EGC, early gastric cancer; HR, hazard ratio; LN, lymph node; PD, poorly differentiated; RFS, Relapse-free survival; SRC, signet ring cell carcinoma; WMD, well-to-moderately differentiated.
